Genetic LifeSpan launches MyHeartCode with Dr. Ernst von Schwarz in Beverly Hills

Genetic LifeSpan introduced MyHeartCode, a new cardiovascular health assessment, at an Aug. 6 premiere in Beverly Hills. The at-home test aims to give people with heart concerns or family history a deeper look at cardiovascular aging and related biological factors.

Why it matters: - MyHeartCode is aimed at people with heart concerns or a family history of cardiovascular disease who want more information before making health decisions. - Genetic LifeSpan is positioning the assessment as a way to add biological context to conversations with healthcare providers, not replace medical care.

What happened: - Genetic LifeSpan officially launched MyHeartCode during an exclusive grand premiere on Aug. 6 in Beverly Hills, California. - The assessment was developed in collaboration with cardiologist Dr. Ernst von Schwarz. - More than 100 invited guests attended the event, including physicians, scientists, health and longevity leaders, Scientific Advisory Board members, company leadership and other guests. - Genetic LifeSpan Founder and CEO Adam Vincent Gilmer and Chief Revenue Officer Jeffrey Mark Gaal attended, along with Scientific Advisory Board members Dr. Laura Capina, Dr. Steven Small, Elliott Greenspan and Dr. Riham Zein.

The details: - MyHeartCode uses advanced epigenetic analysis and intracellular blood data to assess cardiovascular health and cardiovascular age. - The test analyzes up to 3 million CpG sites using methylation science. - Genetic LifeSpan says the analysis reflects biological patterns from roughly the previous three to four months. - The company says that gives a different view than conventional serum testing, which can reflect more immediate physiological conditions. - MyHeartCode combines more than 10 areas of assessment in one digital report. - The report covers cardiovascular age and pace of aging, cardiovascular health, metabolic health, inflammatory health, immune-system health, stress and inflammation biomarkers, nutrient deficiencies, toxin exposure, mitochondrial health and other biological indicators. - The at-home assessment includes sample collection, laboratory processing and a personalized digital report. - MyHeartCode is currently available in the United States. - More information is available at MyHeartCode.bio. - MyHeartCode is intended to provide health information and does not replace diagnosis, treatment or medical care from a qualified healthcare professional.

Between the lines: - The launch fits Genetic LifeSpan’s broader push into health intelligence and longevity-focused testing. - The company is targeting earlier awareness of cardiovascular risk, before health decisions become urgent. - Dr. von Schwarz framed the product as a response to a common problem: many people wait until after a heart event before paying closer attention. - Adam Vincent Gilmer said the goal is to help people ask better questions, have better conversations with doctors and take informed action.

What's next: - Genetic LifeSpan is now expanding the broader introduction of MyHeartCode in the U.S. - The company appears to be building on this launch to grow its portfolio of health intelligence and longevity testing solutions. - Consumers and healthcare professionals can use the digital report as part of ongoing cardiovascular discussions.